VITALIST

VITALIST HEALTH

VITALOS

Pioneering a flexible, developer-friendly ecosystem that revolutionizes wearables design and performance



Vitalist Inc.
(TSX-V: VITA-V, OTCQB: VTLSF)
Corporate Presentation
October 2026

Important Disclaimers & Forward-Looking Statements

CONFIDENTIALITY & GENERAL DISCLAIMER

This presentation is not, and under no circumstances is to be construed as, a prospectus, an advertisement, or a public offering of securities of Vitalist Inc. (“Vitalist” or the “Company”). Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this presentation. No securities commission or similar regulatory authority in Canada, the United States, or any other jurisdiction has reviewed or in any way passed upon the merits of the securities described herein. This presentation is provided for informational purposes only as a general overview of the business of the Company and does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

FORWARD-LOOKING INFORMATION

This presentation contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws and U.S. securities legislation (collectively, “forward-looking statements”). All statements other than statements of historical fact contained herein are forward-looking statements. Forward-looking statements in this presentation include, but are not limited to, statements regarding: the Company’s strategic vision to democratize intelligent wearable firmware; expectations regarding market opportunity, total addressable market (TAM), and industry growth projections; anticipated revenue trajectories, gross margin expansion, and financial performance; expectations regarding the launch, scalability, efficiency, reduced Bill of Materials (BOM) costs, and development timelines of VitalOS™; the execution, timing, product rollouts, retail distribution, and commercial benefits of strategic partnerships (including agreements with Authentic Brands Group / Reebok, Allen Iverson, Benio, Pattern Inc., MicroEJ, and Facer); the integration, clinical validation, subscriber onboarding, and recurring SaaS revenue potential resulting from the acquisition of Somatix, Inc. and the Vitalist Health platform; the commercial launch of VitalOS-enabled devices (including Kinetic); expectations regarding future white-label OAM enterprise licensing agreements; and management’s expectations regarding capital efficiency, liquidity, cash runway, debt servicing, and future financing requirements.

Forward-looking statements are typically identified by words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan,” “goal,” “target,” “potential,” “future,” “continue,” “may,” “will,” “should,” or similar expressions indicating future outcomes or events.

RISKS, UNCERTAINTIES & ASSUMPTIONS

Forward-looking statements are based on reasonable assumptions made by management as of the date of this presentation, including assumptions regarding: economic and market stability; demand for consumer and medical wearable technology; the performance and reliability of VitalOS™; maintaining positive relationships with key licensors, suppliers, manufacturers, and distribution partners; obtaining required regulatory approvals; and the availability of capital on acceptable terms to fund operations and expansion.

However, forward-looking statements are inherently subject to known and unknown risks, uncertainties, and other factors that may cause actual results, level of activity, performance, or achievements to differ materially from those expressed or implied by such statements. These risks include, but are not limited to: the Company’s limited operating history and history of operational losses; risks related to technological obsolescence, intellectual property protection, and rapid competitive shifts in the software and consumer electronics sectors; reliance on key third-party licensing partners (including Authentic Brands Group); supply chain disruptions and component shortages; risks associated with expanding into regulated healthcare and Remote Patient Monitoring (RPM) verticals; risks related to global regulatory compliance, consumer data privacy, and electronic safety standards; ability to manage debt obligations and secure additional capital; and general market, economic, and political conditions. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements contained in this presentation, whether as a result of new information, future events, or otherwise, except as expressly required by applicable securities laws.

THIRD-PARTY DATA & NO FINANCIAL ADVICE

This presentation includes market data, industry statistics, and economic forecasts obtained from independent third-party reports and public industry sources. While the Company believes these sources to be reliable, the Company has not independently verified such data and makes no representation as to its accuracy or completeness. An investment in the Company is speculative and involves a high degree of risk. Investors should conduct their own independent evaluation, review the Company’s continuous disclosure documents, and consult with their own legal, financial, and tax advisors prior to making any investment decision.

CURRENCY & SEDAR+ DISCLOSURE

Unless otherwise indicated, all dollar figures in this presentation are expressed in Canadian Dollars (CAD$). Additional detailed information regarding the Company’s business, risk factors, and financial results can be found in Vitalist’s periodic public filings, including its recent Management’s Discussion and Analysis (MD&A) and Financial Statements, available under the Company's profile on SEDAR+ at www.sedarplus.ca.

Why Vitalist

Vitalist is pioneering an open, developer-friendly ecosystem with its innovative wearable software platform, VitalOS™, and partnering with major brands to enable to creation of next generation wearable design, performance, and battery life.

Proprietary Low-Power OS

VitalOS Engineered to run on lower-resource silicon, extending battery life (7-10 days) while significantly lowering hardware Bill of Materials (BOM) costs for manufacturing partners.

Commercial Validation

5-year exclusive Reebok licensing agreement & Benio Asia partnership targeting the high-volume value market.

High-Margin Healthcare

Expanding into Remote Patient Monitoring (RPM) to unlock predictable, high-margin recurring SaaS revenue.

Scalable & Modular

Turnkey white-label architecture for rapid deployment across non-tech enterprise brands and regional OEMs. Hardware agnostic and modular architecture for rapid deployment.

Multi-Sector Market Capture

Software-first model capturing value across consumer goods, healthcare, and other B2B verticals.

Platform Exit Value Potential

Vitalist aims to aggregate 3-5 million VitalOS™ users within the next 48 months to realize the platform value on a per user basis.[1]

1 Fitbit acquired by Google for ~$72 per user, or $2.1 billion in 2019. Article accessed on July 16, 2025: https://www.fiercehealthcare.com/tech/google-closes-2-1b-acquisition-fitbit-as-justice-department-probe-continues

Global Wearables Market

2025 Market Value
US$92.9 Billion[1]


CAGR 2026 - 2033
12.1%[1]

2033 Market Value
US$229.9 Billion[1]


Largest Market
North America[1]

Fastest Growing Market
Asia Pacific


2025 Product Segmentation[3]



2025 Channel Segmentation[1,2]



2025 Regional Segmentation[4]



VITALIST

1 Grandview Research 2026 (Accessed September 2026). https://www.grandviewresearch.com/industry-analysis/wearable-technology-market
2 Wissen Research 2026 (Accessed September 2026). https://www.wissenresearch.com/wearable-technology-market/
3 Mark and Spark Solutions (Accessed September 2026). https://marksparksolutions.com/reports/global-wearable-technology-market
4 Fortune Business Insights (Accessed September 2026). https://www.fortunebusinessinsights.com/wearable-technology-market-106000

Core Tech & Value Proposition

Delivering "Apple-quality" user experience on easily deployable, low-resource, cost-effective silicon.

Low BOM Cost
VitalOS runs on accessible microcontrollers

7–10 Day Battery Life[1]
Multi-day runtime vs. 1–2 day standard

Rapid Brand Spin-Up
Turnkey launches, with faster, cheaper development cycles

Key Dimension	VITALOS	Proprietary OS (Garmin / Fitbit / Amazfit)	Zephyr / FreeRTOS	WearOS
Availability	**Licensable - Anyone**	Locked-in to their own branded devices	Open Source - Anyone	Limited Licenses; difficult to get approval
Hardware Requirements	**Low**	Low / Medium	Very Low	Very High
Battery Life[1]	**Great battery life (7 - 10+ days)**	Great battery life (7 - 10+ days)	Great battery life (7 - 10+ days)	Max 3 Days
App Ecosystem	**Rapid brand adoption; easy Android transfer**	Limited, mixed 3rd-party support	No app ecosystem	Robust app ecosystem and 3rd party support
Development Effort	**Flexible tools, mobile-like stack**	Fairly modern (Zepp) / primitive (Garmin)	Primitive tools, typically C-based	Flexible tools, mobile-like stack

[1] Based on an average 350mAh smart watch.

VITALIST

Commercial Engine

VITALOS

The Market Impact

A unified OS architecture ensuring that whether a user is an athlete, a timepiece enthusiast, or a clinical patient, their data is handled with high-grade security and unmatched battery efficiency.

Consumer Goods

Reebok

Drastically lowering the barrier to entry
Vitalist's consumer supply chain drops the baseline per-unit manufacturing cost of wearables.

Healthcare

VITALIST HEALTH

Clinical-grade algorithms on consumer wrists.
Hardware-agnostic gesture AI ports seamlessly onto mass-market consumer and enterprise partner devices.

OEMs

BENIO

Selling VitalOS to 3rd party wearable companies to have a continuity in their operating system where they have in the past used multiple ODM's providing multiple user experiences on wearables. Signed first deal with BENIO to do this in Asia.

Consumer Goods

Strategy

Partnering with prominent brands to deploy smart wearable products using the VitalOS platform, to generate revenue and evidence the efficacy of the VitalOS platform.

Execution

Brand Partner: Reebok

By combining Reebok's **89% brand awareness** and **73% owner loyalty in the U.S.** with **$5B+ in annual retail sales across 80 countries**, Reebok provides an instant platform of scale, trust, and global distribution. Extending this powerhouse brand into fitness technology via VitalOS allows Reebok wearables to deliver performance tracking, biometric insights, and connected health directly to a massive, highly engaged athlete community worldwide.

Region: North and South America

Product: Smartwatches


Revenue Model:

Design, produce, and sell Reebok branded smartwatches to distributors, retailers, and via e-commerce channels in a unit transaction model with a percentage royalty to our brand partner.

Status:

5-year Reebok licensing deal signed May of 2025; First product launch in September of 2025; Four products currently in Market; and first VitalOS enabled Reebok product available in October of 2026. Selling in various retailers throughout North and South America.

Wearables Market Value by Channel (US$ Billions)[1,2]



VITALIST

1 Grandview Research 2026 (Accessed September 2026). https://www.grandviewresearch.com/industry-analysis/wearable-technology-market
2 Wissen Research 2026 (Accessed September 2026). https://www.wissenresearch.com/wearable-technology-market/

Reebok **2026/27 Product Line**



RUSH

$79.99

USD MSRP

freeRTOS

In Stores Now



Stride

$99.99

USD MSRP

freeRTOS

In Stores Now

Flagship



Kinetic

$224.99

USD MSRP

VITALOS

October 2026

Limited Edition



Allen Iverson

$249.99

USD MSRP

VITALOS

April 2027



Pulse

$139.99

USD MSRP

freeRTOS

In Stores Now



Icon

$119.99

USD MSRP

freeRTOS

In Stores Now

Health Care

Strategy

Partner with health providers and remote patient monitoring ("RPM") companies to enable them to provide their patients a smart wearable device for their healthcare utilizing the VitalOS platform, with a goal to generate recurring revenue via SaaS, unit sales and monthly monitoring subscriptions.

Execution

Brand: VITALIST HEALTH

Vitalist Health aims to transform continuous gesture tracking into a hardware-agnostic clinical engine, leveraging patent-protected algorithms to monitor falls, medication adherence, and hydration in real time. The platform targets the U.S. Remote Patient Monitoring sector set to grow to $36.3B by 2033[3], operating directly within the North American region which commands a 48.1% share[3] of the global RPM market.

Region: North America

Products: Smartwatches & Bands


Revenue Model:

Design, co-manufacture and deliver white labelled or Vitalist Health branded smart bands to health providers enabling RPM under a SaaS revenue model.


Status:

Completed the acquisition of Somatix, Inc, a gesture recognition algorithm development company April of 2026. First RPM bands designed and manufacturing underway for small batch production and testing. Development focused on algorithm integration into VitalOS

North American RPM Market Value (US$ Billions)[1]



1 Mordor Intelligence 2026 (Accessed September 2026).https://www.mordorintelligence.com/industry-reports/north-america-wearable-medical-devices-market



RPM **2026/27 Product Line**

FLAGSHIP



Lenz

$TBD USD MSRP

VITALOS

Available colors:

NEXT-GEN



Prime

$TBD USD MSRP

VITALOS

Available colors: TBD

Original Equipment Manufacturer

Strategy

Identify and sell VitalOS as a firmware platform solution to wearable OEM's, with the goal of enabling manufacturers, brands, and other businesses to easily and cost effectively spin up new wearable products using VitalOS.

Execution

Technical Partner: MICROEJ

Integrating MicroEJ's proven container architecture, trusted across 250M+ global devices, into our core VitalOS™ stack, we deliver a turnkey software engine designed for rapid OEM deployment. This combined, ultra-low-power solution slashes firmware memory footprints to kilobytes, cuts hardware partner R&D timelines significantly, and provides white-label OEMs with a scalable, modular, high-margin software core capable of 7–10+ day battery performance.

Region: Global


Products: Wrist wearables

Revenue Model:

Deliver a flexible firmware which can be utilized to build a spectrum of wearable products bespoke to the customers needs. Base fee per device, PaaS model for ongoing maintained service, plus engineering service fees where applicable. Asset light model with higher margin, high volumes sales channel, and stickier, lower per unit revenue.

Status:

Completed the initial development of the core VitalOS platform; Signed a letter of intent with Benio to enable their smartwatch products distributed in Asia; Focusing on developer tools and onboarding additional OEM's.



Key Milestones and Growth Strategy

Track Record of Execution

Reebok	2025 - Q2	Signed exclusive Reebok brand licensing agreement	Secured 5-year brand licensing agreement for Reebok smartwatches in North and South America with Authentic Brands Group, unlocking a tier-1 brand to validate the efficacy of the VitalOS platform for a consumer packaged wearable device.
	2025 - Q2	Closed CA$2.5 million private placement	Strengthened balance sheet and injected capital to accelerate firmware R&D, product integration, and commercial go-to-market execution.
	2025 - Q3	Signed Allen Iverson brand license agreement	Expanded global lifestyle licensing portfolio into high-demand basketball, streetwear, and culture-driven consumer wearable segments.
	2025 - Q4	Secured Facer integration for VitalOS™	Transformed visual OS capabilities by granting end-users instant access to a library of 500,000+ customizable watch faces, significantly enhancing consumer engagement and UI differentiation.
	2025 - Q4	Restructured secured debentures	De-risked capital structure by extending debt maturities, lowering interest burdens, and preserving cash flow for commercial scaling.
OTCQB	2025 - Q4	Listed on the OTCQB Venture Market	Expanded access to U.S. institutional and retail investors, enhancing trading liquidity, transparency, and international market visibility.
MICROEJ	2025 - Q4	Partnered with MicroEJ	Integrated MicroEJ's VEE Wear architecture into VitalOS™, optimizing low-resource silicon performance to achieve market-leading 7–10+ day battery life and lower unit BOM costs.
BENIO	2026 - Q1	Executed strategic LOI with Benio	Secured a high-volume hardware distribution partner to scale co-branded smartwatches running VitalOS™ across high-growth Asia-Pacific markets on an OEM basis.
pattern	2026 - Q1	Signed e-commerce distribution deal with Pattern Inc.	Partnered with a premier global e-commerce accelerator to optimize direct-to-consumer digital storefronts, marketplace logistics, and global online conversion.
somatix	2026 - Q2	Acquired Somatix platform IP & assets	Unlocked clinical-grade Remote Patient Monitoring (RPM) algorithms, passive fall detection, and predictive health analytics to integrate into VitalOS and drive high-margin recurring SaaS revenue.
	2026 - Q2	Signed strategic agreement with Health-e Insights	Advanced clinical validation and telemetry data expansion to integrate VitalOS™ wearables into healthcare enterprise networks and remote monitoring workflows.

Upcoming Catalysts & Milestones

VITALOS	2026 - Q4	Commercial launch of VitalOS-enabled Kinetic
	2026 - Q4	Start trials of the Vitalist Health band with RPM partners.
	2027 - Q2	Ship the Allen Iverson special edition smartwatch.
	2027 - Q2	Ship full integrated VitalOS™ health band product.
Reebok	2027 - Q3	Launch next VitalOS™ enabled Reebok product
	2027 - Q3	Release first fully VitalOS™ integrated gesture algorithm into an RPM health product.

VITALIST

VITALOS

Meet Our Leadership



Kalvie Legat

CEO and Director, Kalvie offers over 20 years of extensive experience in finance and capital markets, specializing in corporate finance and institutional sales for small to mid-cap issuers. Since 2019, he has also been actively involved in the consumer electronics business, bringing a well-rounded and dynamic perspective to his expertise.



Carley George

President, Carley is a sales and marketing professional with over 18 years of expertise in account services and relationship development. Her career is marked by recognition as one of Canada's 50 Best Executives in Sales and Marketing by The Globe and Mail (2021), a proven track record of building and nurturing strong partnerships across diverse industries.



David Colleran, CPA

CFO, David has over 17 years of experience in financial reporting, audit, planning, and accounting operations. He is a CPA, and is experienced in building publicly listed, branded, consumer packaged goods and technology companies. David is passionate about developing and scaling small to mid sized businesses.



Charles Herman, M.D.

CSO, Dr. Herman is a surgeon and healthcare executive with over 20 years of experience in clinical practice and medical technology innovation. In addition to leading Somatix, he serves as a Portfolio Manager at Forefront Analytics and has previously held Chief Medical Executive roles for multiple healthcare systems. He holds an MD from Albany Medical College and an MBA from the Wharton School, where he was a Palmer Scholar.



Sean Croft

CPO, Sean Croft brings over 12 years of product and software experience in the consumer and healthcare industries. Since starting his career in computer systems as a software developer, Sean has passionately created and led teams to build products used by users on a global scale.

Meet Our Board



Jared Wolk, CFA

Jared Wolk serves as the Portfolio Manager for Vesta Wealth Partners, a prominent and leading fund within Western Canada. Leveraging a rich foundation of decades of experience in private finance, Jared offers unparalleled insight into market dynamics and investment strategies. He combines this deep knowledge with a genuine passion for innovative businesses, meticulously seeking out and nurturing ventures that align with Vesta Wealth Partners' commitment to delivering exceptional results.



Joanne Hruska, CFA, ICD.D

Joanne Hruska serves as the Chairman of the Board of Vitalist, bringing deep strategic foresight and financial expertise to the company. She also sits on the board of Vitreous Glass Inc. (VCI-V). A distinguished and award-winning investment manager formerly with Aston Hill Funds, Joanne possesses a proven track record in high-level financial management.



John Harding, M.D.

Dr. Harding is a board-certified urologist with three decades of clinical experience in adult urology, male reproductive medicine, and microsurgery. He practiced as a partner at the Michigan Institute of Urology in Metropolitan Detroit, holding an academic appointment at Oakland University William Beaumont School of Medicine. He earned his M.D. from Wayne State University and completed fellowship training at Baylor College of Medicine.



Tyler Rice, CPA, MPAcc

Tyler Rice is the Founding Partner of Rice & Company LLP, an accounting firm specializing in expert advisory and accounting services for start-ups and high-growth organizations. Complementing his firm's focus, Tyler brings significant executive and governance experience, having previously served as President and CEO of Cassiar Gold (GLDC-V), where he also held a key position on its Board.



Tony Natale

Tony Natale joined Vitalist's Board of Directors in August 2026, representing Hantz Group following the Company's acquisition of Somatix. A highly accomplished investment advisor representative, Tony brings deep expertise in financial advisory, capital markets, and corporate planning. He is a genuine enthusiast for the wearable technology and consumer health sectors, and is committed to upholding strong financial oversight and high governance standards on Vitalist's Board.

Vitalist Inc: Capitalization Overview

This slide provides a summary of Vitalist Inc.'s capitalization structure.

Common Shares Outstanding [1]	66,763,533
Options [1]	6,025,000
Warrants [1]	6,460,720
Fully Diluted Shares Outstanding	79,249,253
Royalty Units [2]	6,355,200
Debt [5]	$9.32 million
Market Capitalization [3]	$50.07 million
Enterprise Value [4]	$59.39 million

1 Figure based on June 30, 2026 balances.
2 Represents a right to 3.82% of net sales until May 23, 2027.
3 "Market Capitalization" is a supplementary financial measure and was calculated by multiplying the closing market price of the Common Shares on the TSX Venture Exchange on September 15, 2026 by the shares outstanding. Management believes that Market Capitalization provides a useful measure of the market value of the Company's equity.
4 "Enterprise Value" is a supplementary financial measure and was calculated by adding Market Capitalization and Debt. Management believes that Enterprise Value provides a useful measure of the Company's total value.
5 Figure based on June 30, 2026 balance and exchange rates.

Vitalist Inc: Debt Overview

(All figures in $CAD as at June 30, 2026).

	Accounting Value	Full Cash Value w/ Interest	
Debenture notes [1]	$4.00 million	$6.29 million	Fixed term loan held by largest equity holder; currently 0% interest
Credit facility - (CAD & USD) [2, 3]	$4.00 million	$4.93 million	$12 million line of credit
Factoring line [3]	$0.19 million	$0.20 million	Collateralized against accounts receivable to support working capital
Term facility [3]	$1.13 million	$1.48 million	0% interest; principal paid down quarterly
Total	**$9.32 million**	**$12.90 million**	**Favorable terms on debt to support growth**

1 20% premium will be added to the unpaid balance as at July 1, 2027.
2 Accounting value does not include interest, which is presented in accounts payables
3 Translated balances at 1.4209.

Vitalist Inc. | TSXV: VITA | OTCQB: VTLSF



PHONE
+1 (403) 560-9635

WEBSITE
www.vitalist.ca

EMAIL
ir@vitalist.ca

ADDRESS
Vitalist Inc. - 222 3rd Avenue SW, Calgary. Alberta,Canada

Vitalist Health - 3 Columbus Circle, 15th Floor New York, NY

INVESTOR RELATIONS
Walter Frank
IMS Investor Relations
vitalist@imsinvestorrelations.com
(203) 972-9200

VITALIST VITALIST HEALTH VITALOS